Financials
Financial year 2025
Janssen Pharmaceutica from Beerse, company number BE0403834160, closed financial year 2025 with a result of € 1.5 billion after tax. For that financial year Janssen Pharmaceutica recorded revenue of € 21.8 billion and equity of € 11.7 billion. Compared with financial year 2024, the result moved from € 2.6 billion to € 1.5 billion. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 22, 2026.
€ 11.7 billion
▲ 12% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 1.5 billion
▼ 44% vs 2024
Profit after tax over the fiscal year.
€ 24.7 million
▼ 44% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 250 million paid out
17 % of the profit went to the shareholders, mostly to Johnson & Johnson (100 % of the shares). That is where the money ends up.
People and assets in 2025
5,324.5
▲ 114.6 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 966.5 million
▲ 3% vs 2024
€ 181,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 46.1 million
▼ 4% vs 2024
Of which on lease € 38.7 million.
Debts at end 2025
€ 4.3 billion
▲ 98% vs 2024
€ 300.9 million is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 4.2 billion
▼ 19% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 60 days on average.
€ 355.7 million
▼ 7% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 21,355,073,201 | € 22,206,076,623 | € 22,587,271,267 | € 21,788,177,348 | ▼ 4% |
| Profit after taxes | € 1,955,747,693 | € 2,416,065,934 | € 2,633,412,401 | € 1,462,262,938 | ▼ 44% |
| Equity | € 8,774,071,290 | € 9,830,842,656 | € 10,464,318,045 | € 11,677,693,137 | ▲ 12% |
| Total debts | € 9,673,065,754 | € 9,031,970,854 | € 9,982,572,272 | € 9,344,524,179 | ▼ 6% |
| Cash | € 31,517,401 | € 9,540,741 | € 44,341,081 | € 24,744,614 | ▼ 44% |
| Land & buildings | € 114,098,970 | € 133,190,780 | € 106,084,603 | € 155,230,478 | ▲ 46% |
| Retained profit | € 7,156,548,289 | € 8,213,541,175 | € 8,846,953,576 | € 10,059,216,514 | ▲ 14% |
| Dividend | € 3,000,000,000 | € 1,359,073,048 | € 2,000,000,000 | € 250,000,000 | ▼ 87% |
| Bank debt | € 4,694,236,399 | € 4,538,474,876 | € 2,166,731,868 | € 4,280,194,165 | ▲ 98% |
| Balance sheet total | € 19,279,919,705 | € 19,615,807,471 | € 20,944,078,135 | € 21,578,214,816 | ▲ 3% |
| Employees (FTE) | 5,050.2 | 5,159.2 | 5,209.9 | 5,324.5 | ▲ 114.6 |
Key figures of Janssen Pharmaceutica, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to Janssen Pharmaceutica?
What happened at Janssen Pharmaceutica in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Tim De Kegel stepped down as director. NBB
- Bart Van Waeyenberge stepped down as director. NBB
- Robin Gommers stepped down as director. NBB
- Hilde Claes stepped down as director. NBB
- Frank Lambrechts stepped down as director. NBB
- Bart Philips stepped down as director. NBB
- Tom Aelbrecht stepped down as director. NBB
- Nicoleta-Roxana Botea stepped down as director. NBB
In short
From € 2 billion profit in 2022 to € 1.5 billion profit in 2025.
Paid € 390.5 million in corporate taxes since 2022.
Best year ever: 2024, with € 2.6 billion profit.
Paid out € 6.6 billion in dividends to the owners in total.
Management
The shares are held by Johnson & Johnson (100%) and Johnson & Johnson International (0%). It owns 100% of JANSSEN-CILAG S.p.A., 100% of J.C. General Services, 100% of JANSSEN-CILAG, 99% of JANSSEN-CILAG INTERNATIONAL and 0% of JOHNSON & JOHNSON MEDICAL itself.
Directors
According to the 2025 annual accounts
Peter Janssens
Director
since 2023 · until 2028
Ulrike Philippar
Director
since 2023 · until 2028
Tim De Kegel
Director
since 2025 · until 2031
Bart Van Waeyenberge
Director
since 2025 · until 2031
Kobe Naesens
Director
since 2021 · until 2027
Marleen Hoebus
Director
since 2022 · until 2028
since 2025 · until 2026
Robin Gommers
Director
since 2025 · until 2031
Steven Oliver
Director
since 2024 · until 2029
Hilde Claes
Director
since 2025 · until 2031
since 2021 · until 2026
Frank Lambrechts
Director
since 2025 · until 2031
since 2025 · until 2031
Vicky Bruggeman
Director
since 2021 · until 2025
since 2025 · until 2031
Stefan Bouckaert
Director
since 2024 · until 2026
Nicoleta-Roxana Botea
Director
since 2024 · until 2030
Shareholders
Johnson & Johnson
100%
Johnson & Johnson International
0%
Participations
Establishments
Establishment units
Physical locations of this company
Turnhoutseweg 30
2340 Beerse
Lammerdries 55
2250 Olen
Active since 1 January 1800
Antwerpseweg 15-17
2340 Beerse
Active since 1 January 1945
Janssen-Pharmaceuticalaan 3
2440 Geel
Active since 1 January 1945
Antwerpsesteenweg 37
2350 Vosselaar
Active since 1 January 1945
Rue du Bois de la Hutte(H-G) 7
7110 La Louvière
Active since 1 October 2011
Rue du Bois de la Hutte(H-G) 5
7110 La Louvière
Active since 1 January 2012
Leonardo da Vincilaan 15
1831 Machelen (Brab.)
Active since 1 May 2012
de Meeûssquare 23
1000 Brussel
Active since 8 May 2015
Rue du Luxembourg(CO) 5
6180 Courcelles
Active since 1 May 2015
Technologiepark-Zwijnaarde 73
9052 Gent
Active since 1 October 2021
Suzanne Tassierstraat 8
9052 Gent
Active since 22 May 2023
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0403.834.160
- VAT number
- BE 0403.834.160
- Registered office
- Turnhoutseweg 30, 2340 Beerse
- Names & denominations
- Janssen Research & Development, Johnson & Johnson, J&J, Johnson & Johnson Innovative Medicine, J&J Innovative Medicine · Janssen Pharmaceutica
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 23 October 1934
- Peppol
- Active · Active since 18 Dec 2025
- Activities · NACE
Vervaardiging van geneesmiddelen
Computerinfrastructuur, gegevensverwerking, hosting en aanverwante activiteiten
Overige technische testen en toetsen
Technische testen en analyses
Gegevensverwerking
Gegevensverwerking, webhosting en aanverwante activiteiten